Navigation Links
Silence Therapeutics and InteRNA Technologies Sign Collaboration to Develop Novel microRNA Therapeutics
Date:9/11/2011

a>)

InteRNA Technologies is a Dutch early-stage drug discovery and development company that develops pathway targeted cancer therapies based on the unique functions of its proprietary microRNAs ("miRNAs").

InteRNA takes an holistic approach in R&D to unravel the biological role of its proprietary miRNAs focusing on the demonstration of their function in a number of cancer indications through functional screens, using its proprietary lentiviral-based miRNA expression library, currently the largest available. This approach results in the identification of novel, "drugable" targets, providing a steady basis for further validation and drug development.

InteRNA Technologies was incorporated in December 2006 by Aglaia Oncology Fund and has established close relationships with the research groups of its founders Edwin Cuppen, PhD, and Eugene Berezikov, PhD, of the Hubrecht Institute (Utrecht, the Netherlands), leading scientific groups in the field of miRNA research. The company further has a series of R&D partnerships with Dutch- and US-based academic hospitals and research institutes.

About MicroRNAs (miRNAs)

MicroRNA (miRNA) are naturally occurring, non-coding strands of RNA that trigger the RNA interference pathway. They result from an extensive processing route in which a long RNA transcript, folded in a hairpin structure, is cleaved into short strands of approximately 22 nucleotides - the miRNA molecules.

MiRNAs regulate gene expression by controlling the efficiency of messenger RNA (mRNA) translation - the process of translating genetic information into proteins. The miRNA binds to its target sequence in mRNA transcripts, leading to translational repression or mRNA degradation. As a result, the production of the protein encoded by that particular mRNA sequence is inhibited.

So far, approximately 940 human miRNA sequences have been documented. For many of these it is not clear what genes they target. How
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
2. Silence Therapeutics Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting
3. Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
4. Silence Therapeutics Provides Year-end Update
5. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
6. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
7. Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Silence Therapeutics Announces Board Changes
10. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
11. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... CHICAGO and SOUTH SAN ... -- The Pulmonary Fibrosis Foundation (PFF) and ... announced that the organizations are partnering on a ... diagnostic experiences with interstitial lung diseases (ILDs), including ... Patient Journey (INTENSITY) survey will assess the steps ...
(Date:8/27/2015)... MENLO PARK, Calif. , Aug. 27, 2015 /PRNewswire/ ... the "Company"), a biopharmaceutical company focused on the development ... it will release its year-end financial results for the ... 4, 2015. DelMar,s management team will ... for investors, analysts and other interested parties on Friday, ...
(Date:8/27/2015)... August 27, 2015 The global ... reach USD 3.96 billion by 2022, according to a ... of chronic venous disorders such as deep vein thrombosis, ... serve as the key driver.      (Logo: ... injuries are also expected to boost market growth over ...
Breaking Medicine Technology:Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 2Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 4DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 2DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 3Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 2Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 3Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 4Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 5
... ANGELES, April 17, 2007 /PRNewswire/ -- Researchers from ... presented,strong evidence today that an antibiotic typically prescribed ... types of cancers. , Q. Ping Dou, Ph.D., ... lab announced the findings of their study showing,that ...
... LOS ANGELES--(BUSINESS WIRE)--Apr 17, 2007 - ZIOPHARM ... of preclinical,data strongly supportive of the development ... demonstrates very high,bioavailability when administered orally; in ... well suited to oral,administration. These data were ...
Cached Medicine Technology:Alzheimer's Drug Shows Promise in Fighting Cancer 2ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR 2ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR 3
(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... ... array of instruments available for quantitative PCR (qPCR) in the last ... higher throughput and reduced operating costs. On the flipside, where do lab managers, ...
(Date:8/27/2015)... PA (PRWEB) , ... August 27, 2015 , ... ... Health Network , is one of just 20 adult-only medical centers in the ... for people with failing hearts and lungs. The Extracorporeal Life Support Organization ...
(Date:8/27/2015)... ... 27, 2015 , ... The Naderi Center is proud to announce that its ... procedure to improve submental fat. The first and only Food and Drug Administration ... Dr. Kulak is the only Board Certified surgeon in the D.C., Maryland, Virginia area ...
(Date:8/27/2015)... ... August 27, 2015 , ... More destinations and stores are becoming pet-friendly, ... Amica Insurance is sharing some tips to help your whole family travel safely and ... travel with pets each year. Amica is sharing the following tips from the American ...
(Date:8/27/2015)... , ... August 27, 2015 ... ... Swan Analysis signed a partnership agreement for quality market research promotion on ... elaborated by Black Swan Analysis. , Commenting on the partnership agreement, Natalie ...
Breaking Medicine News(10 mins):Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 2Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:Amica Unleashes 5 Tips for Safe Traveling with Pets 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3
... CEL-SCI Corporation (NYSE AMEX: CVM ) announced today financial results ... results: , , ... of 41% compared to a net loss of $3,210,294 during the same quarter ... loss per common share for the quarter ended March 31, 2009 was $0.02 ...
... 15 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME/TSX: ... quarter ended March 31, 2009. Amounts, unless specified ... accordance with Canadian Generally Accepted Accounting Principles (Canadian ... 2009, the exchange rate was CAD$1.00=US$0.7928.Results of OperationsWe ...
... PARIS, FRANCE The International Union for Health ... Health Education (SOPHE) are pleased to release today special, ... and quality assurance systems of global capacity in health ... Education & Behavior (Vol. 36, No. 3, June ...
... Help Employers and Business Owners Plan for Pandemic ImpactPLYMOUTH ... hosting two free webinars on May 19, 2009 to ... Following the webinar Health Advocate will release a special ... summarizing steps for employers to take.Two experts - ...
... May 15 Within weeks, the University of ... campus that will provide a springboard for new discoveries, ... wise investment for U-M,s future.U-M,s purchase of the former ... North Campus will be completed on June 16, said ...
... of Medicine (BUSM) have found a high frequency ... the largest neonatal intensive care units (NICUs) in ... methods could reduce the vast number of hospital ... in the journal Infection Control and Hospital ...
Cached Medicine News:Health News:CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results 2Health News:CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results 3Health News:CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results 4Health News:CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results 5Health News:Cardiome Reports First Quarter Results 2Health News:Cardiome Reports First Quarter Results 3Health News:Cardiome Reports First Quarter Results 4Health News:Special journal issues released on global health promotion and health education 2Health News:Experts to Discuss Worksite Preparedness Measures During May 19th Pandemic Flu Webinars 2Health News:U-M Purchase of Former Pfizer Facility Nears Completion, Paving the Way For Research Expansion and Job Creation 2Health News:BUSM researchers find gram-negative rods in two Philippine neonatal intensive care units 2
Express Elyte Systems....
... 1650 has minimal requirements for ... 2 L/test), reagent consumption (as ... water consumption (25 L/hour) - ... universal rack handler facilitates continuous ...
Iron Total (TIBC) (Iron Buffer + Iron Color=Std.). An Automated analyzer test kits....
For the quantitative determination of Iron and IBC in serum. Colorimetric method utilizing ferrozine. Endpoint procedure measured at 560 nm. Linearity: 500 ug/dl....
Medicine Products: